Pharma Focus Asia

Roswell Park Comprehensive Cancer Centre Invests US$98 million to Open Cell and Gene Therapy Hub in New York, USA

Introduction:
Roswell Park Comprehensive Cancer Centre invests US$98 million to open cell and gene therapy manufacturing facility in USA.

Features:
The US$98 million centre will revolutionise the field of life-saving therapies by significantly enhancing research and development capabilities. Moreover, this facility will serve as a catalyst for the expansion of the cell and gene therapy sector.

This state-of-the-art facility expands the existing cell and gene therapy research capacity at Roswell's Therapeutic Cell Production Facility, from six to 20 specialised clean rooms making it now the largest academic cell and gene therapy research and manufacturing facility in the United States.

The new facility is set to optimise the entire cell therapy development pipeline, significantly reducing the time from research to production. In addition, it will help to develop and sell new therapies, bring in talented people focuisng on innovation.

The new facility aims to develop groundbreaking treatments with the potential to improve the outcomes for individuals fighting cancer.

Specifications:
Name    Roswell Park Comprehensive Cancer Center
Type      New Construction
Budget   US$98 million

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference